Suboxone vs. Sublocade: Which Buprenorphine Treatment Is Right for You?

At-a-Glance Comparison: Suboxone vs. Sublocade

Key Takeaways

• Suboxone is where most people start. The daily film or tablet format offers flexibility, easy dose adjustments, and telehealth accessibility — making it the standard first-line buprenorphine treatment.
• Sublocade is where stable patients often want to go. Once recovery is established, a monthly injection eliminates the daily reminder of treatment and removes any possibility of a missed dose.
• Both use the same active ingredient. Buprenorphine drives the clinical effect in both medications. The difference is delivery, not pharmacology.
• Sublocade requires 7 days of stability on sublingual buprenorphine first. You cannot jump directly to the injection — your body and your provider need to confirm the right dose before committing to a 30-day release.
• Sublocade has no dental risk. Because it is an injection, buprenorphine never contacts the teeth or mouth — a clinically meaningful distinction for patients who have been on sublingual medications long-term.
• A 2026 real-world study found that patients adherent to monthly injectable buprenorphine had $15,017 lower annual non-medication medical costs per patient compared to those on other OUD medications — driven by fewer hospitalizations, ER visits, and detox episodes.

Why Two Different Buprenorphine Medications Exist

Both Suboxone and Sublocade were designed to solve the same clinical problem — keeping buprenorphine consistently in the body to prevent withdrawal, reduce cravings, and block the effects of other opioids. But they were built for different moments in recovery.

Suboxone was designed for flexibility. Early recovery often requires frequent dose adjustments as the brain stabilizes and individual needs become clearer. A daily medication that can be titrated at any visit — and that the patient controls at home — fits that phase well. It is also accessible via telehealth, which means it can reach patients in rural areas or those who cannot easily get to a clinic.

Sublocade was designed for consistency. Once someone is stable on a known buprenorphine dose, the daily act of taking medication can become a friction point — a daily reminder of treatment status, a vulnerability to missed doses during stressful periods, or simply a management burden. A once-monthly injection handled entirely by the provider removes all of that.

Thinking about them as sequential tools rather than competing alternatives is often more useful. For many patients, the path looks like this: start on Suboxone → stabilize over weeks to months → transition to Sublocade for long-term maintenance.

Why Suboxone Contains Naloxone — and Sublocade Does Not

This is one of the most common points of confusion between these two medications, and the explanation is simple.

Suboxone contains naloxone as a misuse deterrent. Because patients take Suboxone at home and carry it with them, there is a theoretical risk that the film or tablet could be dissolved and injected for a stronger effect. Naloxone is included specifically to prevent this — if the medication is injected, the naloxone activates and immediately triggers withdrawal, making injection counterproductive. When taken sublingually as intended, naloxone has very low absorption and does not significantly affect the buprenorphine effect.

Sublocade contains only buprenorphine — because no deterrent is needed. The injection is administered exclusively by a certified healthcare provider in a clinical setting. There is no medication for the patient to take home, store, or potentially misuse. The logistics of the delivery method make the naloxone component unnecessary.

From a clinical standpoint, both medications deliver buprenorphine to the brain in the same way. The naloxone difference is an abuse-deterrence design choice, not a pharmacological one.

The Lifestyle Factor: Which Fits Your Recovery?

This is not purely a clinical decision. The better medication is the one a patient will actually stay on — and that depends heavily on daily life.

Suboxone May Be the Better Fit If:

• You are newly starting treatment and your dose still needs adjustment
• You value direct control over your medication and timing
• You prefer the ability to take your medication privately at home
• You live far from a clinic and rely on telehealth for care
• Your insurance coverage for injectables is limited or requires prior authorization
• You are in a phase of recovery where flexibility matters most

Sublocade May Be the Better Fit If:

• You have been stable on a consistent daily buprenorphine dose for at least 7 days
• You struggle with remembering to take medication daily
• You travel frequently and find managing a daily prescription inconvenient
• You want to remove all controlled medication from your home environment
• Dental health is a concern and you want to eliminate sublingual film exposure
• You want the highest possible protection against "skipping a day" during a difficult moment
• You are ready for a quieter, more background role for your medication in daily life

Side Effects: What's Different Between the Two

Both medications share buprenorphine's general side effect profile — constipation, headache, nausea, insomnia, and sweating are reported across both formulations. The differences come from the delivery method.

Suboxone: The Dental Health Concern

In January 2022, the FDA issued a formal safety communication about dental problems associated with transmucosal (sublingual and buccal) buprenorphine products — including Suboxone. Reported issues include tooth decay, cavities, oral infections, and in some cases tooth loss, appearing anywhere from two weeks to several years after starting treatment.

The mechanism is well established: sublingual films and tablets lower the pH of the mouth when held under the tongue. That acidic environment can erode enamel and disrupt the oral microbiome over time, increasing cavity and gum disease risk. Published research in PMC confirms this is a class effect of transmucosal buprenorphine formulations.

The FDA's current guidance for Suboxone users:

• After the film or tablet fully dissolves, take a large sip of water and gently swish it around the mouth
• Swallow the water
• Wait at least one hour before brushing teeth
• Maintain regular dental checkups and inform your dentist you are on sublingual buprenorphine

Sublocade carries no dental risk whatsoever — buprenorphine never contacts the mouth.

Sublocade: The Injection Site Reaction

The most commonly reported side effects specific to Sublocade involve the injection site. A small, firm lump or nodule at the abdomen (the only approved injection site for Sublocade) is expected — it is the ATRIGEL® polymer depot that releases medication over the month. This nodule is not a sign of a problem; it is the medication working as designed.

Additional injection site reactions reported in clinical trials (occurring in more than 5% of patients) include itching and pain at the site. These are generally mild. More serious but rare reactions — abscess, skin breakdown — have been reported post-marketing, typically linked to improper injection technique.

Side Effect Comparison

Success Rates: What the Evidence Shows

Both medications are built on the same pharmacology, so direct efficacy comparisons are nuanced. What the evidence does show clearly is that adherence — staying on medication consistently — is the primary driver of outcomes. And Sublocade has a structural advantage here.

Sublocade Phase 3 Clinical Data

In the pivotal Phase 3 trial, 28% of patients on Sublocade plus counseling achieved treatment success — defined as freedom from illicit opioids for at least 80% of weeks in a 24-week study — compared to 2% on placebo plus counseling.

The Adherence Advantage of Monthly Injection

Starting Sublocade on Day 1 resulted in 66.4% of patients receiving their second injection versus 54.5% of patients with standard induction. This gap matters because the early weeks of treatment carry the highest dropout risk — and every additional injection a patient receives means more days protected by consistent buprenorphine levels.

A 2026 real-world retrospective study published in Frontiers in Public Health found that patients adherent to monthly injectable buprenorphine experienced the lowest rates of inpatient admissions, emergency department visits, and detoxification services across all treatment groups — with $15,017 lower annual non-medication medical costs per patient compared to those on other OUD medications.

The mechanism behind these outcomes is straightforward: it is structurally impossible to miss a Sublocade dose after the injection has been given. With Suboxone, even motivated patients can miss doses during difficult periods. Sublocade removes that vulnerability entirely for 30 days at a time.

What "Success" Looks Like Varies by Person

For a newly diagnosed patient still figuring out their therapeutic dose, Suboxone's flexibility may produce better outcomes than locking into a 30-day injectable commitment too early. For someone stable on a known dose who has had repeated adherence struggles, Sublocade may be the difference between continued engagement and dropout. Neither medication is universally superior — the evidence supports both as highly effective when used in the right clinical context.

Switching from Suboxone to Sublocade: How It Works

Sublocade is not a standalone first-line treatment. The FDA requires at least 7 days of dose stabilization on transmucosal (sublingual or buccal) buprenorphine before the first Sublocade injection. This stabilization period accomplishes two things: it confirms the patient can tolerate buprenorphine, and it establishes the daily dose that the monthly injection will need to replicate.

The Standard Transition Protocol

• Stabilize on Suboxone for a minimum of 7 days with controlled withdrawal symptoms and no supplemental dosing needed
• Confirm the appropriate daily dose — this determines which Sublocade formulation the provider will use
• Receive the first injection — 300 mg for the first two months (loading dose), administered subcutaneously in the abdomen
• Second injection can be given as early as 1 week later to build blood levels faster, or at the standard 4-week interval
• Maintenance dose — 100 mg monthly after the loading period, with the option to increase to 300 mg if the clinical response is insufficient

What Happens to Sublocade When You Stop

One of the less-discussed features of Sublocade is its very long tail. After the last 100 mg maintenance injection, buprenorphine remains detectable in the body for approximately 12 months. After the last 300 mg dose, the tail is even longer. This slow, natural decline means that stopping Sublocade is not an abrupt event — the medication tapers itself gradually over many months, which many patients and providers find clinically useful when discontinuation is eventually appropriate.

Cost: A Real Difference Worth Understanding

The cost gap between Suboxone and Sublocade is significant and should be part of any honest conversation about choosing between them.

With insurance — including most Medicaid plans and commercial plans — Sublocade coverage is available, though prior authorization is commonly required. Indivior (the manufacturer) offers a patient savings program for commercially insured patients. Patients on Medicaid, Medicare, or other government programs should check their specific plan's coverage directly.

For patients without strong insurance coverage, generic sublingual buprenorphine/naloxone is substantially more affordable and clinically equivalent in efficacy for patients with good adherence.

Frequently Asked Questions

Can I switch directly from Suboxone to Sublocade?

Yes — and this is actually the standard pathway. You need to be stable on your current Suboxone dose for at least 7 days with controlled symptoms before your provider can give you the first Sublocade injection. The stabilization period allows the provider to confirm the right dose before committing to a 30-day release.

Does Sublocade work better than Suboxone?

For patients with adherence challenges, Sublocade often produces better outcomes — not because the pharmacology is superior, but because it is impossible to miss a dose once the injection has been given. For stable, adherent patients, both are clinically equivalent in efficacy. The choice comes down to lifestyle, access, and personal preference.

Is Sublocade covered by insurance?

Most major commercial insurance plans and many Medicaid plans cover Sublocade, though prior authorization is commonly required. Coverage varies by state and plan. The manufacturer's patient assistance program may reduce out-of-pocket costs for commercially insured patients who qualify. Medicare coverage is more variable.

What does the Sublocade injection feel like?

The injection is given subcutaneously in the abdomen using a standard needle. Most patients report mild to moderate discomfort at the injection site. A firm, palpable nodule typically forms at the site and may remain for several weeks — this is the medication depot and is expected. Redness or itching at the site is also common and usually resolves on its own.

Can I get Suboxone through telehealth but not Sublocade?

Suboxone can be initiated, managed, and refilled entirely through telehealth — which is how Bicycle Health delivers care. Sublocade requires an in-person visit for each injection, since the medication must be administered by a certified healthcare provider. Patients interested in Sublocade may need to coordinate with a local certified clinic for the injection appointments while managing their overall care through a telehealth provider.

Will Sublocade show up on a drug test?

Standard drug panels do not typically test for buprenorphine. Expanded panels may detect it. If you are subject to workplace or legal drug testing while on Sublocade, inform the testing administrator and provide documentation of your prescription. Because buprenorphine remains detectable for up to 12 months after the last Sublocade injection, this is especially relevant if you stop treatment.

What happens if I miss a Sublocade appointment?

According to the prescribing information, occasional delays of up to two weeks are not expected to have a clinically significant impact on the treatment effect. If you miss a scheduled injection, contact your provider as soon as possible to reschedule. The next dose should be given no less than 26 days after the missed dose.